{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:35:43Z","timestamp":1792218943357,"version":"4.4.0"},"reference-count":63,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: Naltrexone, a medication for addiction treatment (MAT), is an FDA-approved medication recommended for the treatment of alcohol use disorder (AUD). Despite the high prevalence of AUD and efficacy of naltrexone, only a small percentage of individuals with AUD receive treatment. Objectives: To identify trends for the prescription of naltrexone in AUD admissions in substance use treatment centers across the U.S. Methods: Data from the 2000\u20132018 U.S. Treatment Episode Data Set: Admissions (TEDS-A) were used in temporal trend analysis of naltrexone prescription in admissions that only used alcohol. Data from the 2019 National Survey of Substance Abuse Treatment Services (N-SSATS) were also used to characterize medication use among AUD clients across different treatment service settings. Results: Treatment of AUD with naltrexone was 0.49% in 2000 and tripled from 0.53% in 2015 to 1.64% in 2018 in AUD admissions (p &lt; 0.0001 for the Cochran\u2013Armitage trend test). Women, middle-aged adults, and admissions for clients living in the Northeast U.S. were more likely to be prescribed naltrexone than their respective counterparts, as were admissions with prior treatment episodes and referrals through alcohol\/drug use care providers, who paid for treatment primarily through private insurance, used alcohol daily in the month prior to admission, and waited 1\u20137 days to enter treatment. Naltrexone was more commonly prescribed by AUD admissions compared to acamprosate and disulfiram and was more frequently prescribed in residential and outpatient services as opposed to hospital inpatient services. Conclusions: Naltrexone remains underutilized for AUD, and factors that influence prescription of medication are multifaceted. This study may contribute to the creation of effective interventions aimed at reducing naltrexone disparities for AUD.<\/jats:p>","DOI":"10.3390\/ijerph18168884","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T21:59:00Z","timestamp":1629755940000},"page":"8884","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-220X","authenticated-orcid":false,"given":"Fares","family":"Qeadan","sequence":"first","affiliation":[{"name":"Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8380-0390","authenticated-orcid":false,"given":"Nana A.","family":"Mensah","sequence":"additional","affiliation":[{"name":"Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-6257","authenticated-orcid":false,"given":"Lily Y.","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin F.","family":"Madden","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla L.","family":"Venner","sequence":"additional","affiliation":[{"name":"Department of Psychology, Center on Alcohol, Substance Use, and Addiction (CASAA), University of New Mexico, Albuquerque, NM 87131, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"English","sequence":"additional","affiliation":[{"name":"Albuquerque Area Southwest Tribal Epidemiology Center, Albuquerque, NM 87110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"ref_1","unstructured":"National Institute on Alcohol Abuse and Alcoholism (2021, February 04). Alcohol Facts and Statistics, Available online: https:\/\/www.niaaa.nih.gov\/publications\/brochures-and-fact-sheets\/alcohol-facts-and-statistics#:~:text=An%20estimated%2095%2C0005%20people,poor%20diet%20and%20physical%20inactivity."},{"key":"ref_2","unstructured":"SAMHSA (2021, February 04). 2019 National Survey on Drug Use and Health (NSDUH). Table 5.4A\u2014Alcohol Use Disorder in Past Year among Persons Aged 12 or Older, by Age Group and Demographic Characteristics: Numbers in Thousands, 2018 and 2019, Available online: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHDetailedTabs2018R2\/NSDUHDetTabsSect5pe2018.htm#tab5-4a."},{"key":"ref_3","unstructured":"World Health Organization (2019). Global Status Report on Alcohol and Health 2018, World Health Organization."},{"key":"ref_4","unstructured":"Centers for Disease Control and Prevention (2021, February 06). Excessive Alcohol Use, Available online: https:\/\/www.cdc.gov\/chronicdisease\/resources\/publications\/factsheets\/alcohol.htm."},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (2021, February 08). Alcohol Related Disease Impact (ARDI) Application, Available online: https:\/\/www.cdc.gov\/ARDI."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.amepre.2015.05.031","article-title":"2010 national and state costs of excessive alcohol consumption","volume":"49","author":"Sacks","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 Alcohol Use Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/00952990.2018.1528265","article-title":"State-of-the-art behavioral and pharmacological treatments for alcohol use disorder","volume":"45","author":"Ray","year":"2019","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1007\/s11606-020-06073-w","article-title":"Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population","volume":"35","author":"Huskamp","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jpsychires.2015.07.016","article-title":"Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses","volume":"69","author":"Rubinsky","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","article-title":"Barriers to use of pharmacotherapy for addiction disorders and how to overcome them","volume":"13","author":"Oliva","year":"2011","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1176\/appi.ajp.2018.17060688","article-title":"Medication-Assisted treatment for alcohol-dependent adults with serious mental illness and criminal justice involvement: Effects on treatment utilization and outcomes","volume":"175","author":"Robertson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/acer.13285","article-title":"Drinking, Alcohol Use Disorder, and Treatment Access and Utilization among U.S. Racial\/Ethnic Groups","volume":"41","author":"Vaeth","year":"2017","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_17","unstructured":"Substance Abuse and Mental Health Services Administration, and National Institute on Alcohol Abuse and Alcoholism (2015). Medication for the Treatment of Alcohol Use Disorder: A Brief Guide, HHS Publication. Vol No. (SMA) 15-4907."},{"key":"ref_18","unstructured":"SAMHSA (2021, February 06). Medication-Assisted Treatment (MAT), Available online: https:\/\/www.samhsa.gov\/medication-assisted-treatment."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.9740\/mhc.2019.11.392","article-title":"Treatment outcomes of long-acting injectable naltrexone versus oral naltrexone in alcohol use disorder in veterans","volume":"9","author":"Leighty","year":"2019","journal-title":"Ment. Health Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"Jama"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: A review","volume":"320","author":"Kranzler","year":"2018","journal-title":"Jama"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"R\u00f6sner, S., Hackl-Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M., and Soyka, M. (2010). Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev., 12.","DOI":"10.1002\/14651858.CD001867.pub3"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/abm\/kax053","article-title":"Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment during a Mobile Health Intervention","volume":"52","author":"Dermody","year":"2018","journal-title":"Ann. Behav. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/HRP.0000000000000079","article-title":"Pharmacotherapy for alcohol use disorder: Current and emerging therapies","volume":"23","author":"Swift","year":"2015","journal-title":"Harv. Rev. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Murphy, C.E., Wang, R.C., Montoy, J.C., Whittaker, E., and Raven, M. (2021). Effect of extended-release naltrexone on alcohol consumption: A systematic review and meta-analysis. Addiction.","DOI":"10.1111\/add.15572"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107694","DOI":"10.1016\/j.drugalcdep.2019.107694","article-title":"Trends in first-time treatment admissions for older adults with alcohol use disorder: Availability of medical and specialty clinical services in hospital, residential, and outpatient facilities","volume":"205","author":"Huhn","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drugalcdep.2013.01.016","article-title":"Use of naltrexone for alcohol use disorders in the Veterans\u2019 Health Administration: A national study","volume":"132","author":"Iheanacho","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"ref_28","unstructured":"Alderks, C.E. (2017). Trends in the Use of Methadone, Buprenorphine, and Extended-Release Naltrexone at Substance Abuse Treatment Facilities: 2003\u20132015 (Update), CBHSQ Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder among Adolescents and Young Adults, 2001\u20132014","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.drugalcdep.2017.06.011","article-title":"Variation in receipt of pharmacotherapy for alcohol use disorders across racial\/ethnic groups: A national study in the U.S. Veterans Health Administration","volume":"178","author":"Williams","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"ref_31","first-page":"e277","article-title":"First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario","volume":"63","author":"Spithoff","year":"2017","journal-title":"Can. Fam. Physician"},{"key":"ref_32","unstructured":"Substance Abuse and Mental Health Services Administration, and Center for Behavioral Health Statistics and Quality (2019). Treatment Episode Data Set (TEDS): 2017. Admissions to and Discharges from Publicly-Funded Substance Use Treatment."},{"key":"ref_33","unstructured":"Substance Abuse and Mental Health Services Administration (2020). National Survey of Substance Abuse Treatment Services (NSSATS): 2019. Data on Substance Abuse Treatment Facilities."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1081\/ADA-200032281","article-title":"Which substance abuse treatment facilities offer dual diagnosis programs?","volume":"30","author":"Mojtabai","year":"2004","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"108067","DOI":"10.1016\/j.drugalcdep.2020.108067","article-title":"The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US","volume":"212","author":"Stahler","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jsat.2004.06.001","article-title":"A conceptual framework for drug treatment process and outcomes","volume":"27","author":"Simpson","year":"2004","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/ADM.0b013e3181d41ddb","article-title":"Adoption and implementation of medications in addiction treatment programs","volume":"5","author":"Knudsen","year":"2011","journal-title":"J. Addict. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.15288\/jsad.2012.73.413","article-title":"Advancing recovery: Implementing evidence-based treatment for substance use disorders at the systems level","volume":"73","author":"Schmidt","year":"2012","journal-title":"J. Stud. Alcohol Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014Tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Anderson, E.S., Chamberlin, M., Zuluaga, M., Ullal, M., Hawk, K., McCormack, R., D\u2019Onofrio, G., and Herring, A.A. (2021). Implementation of Oral and Extended-Release Naltrexone for the Treatment of Emergency Department Patients with Moderate to Severe Alcohol Use Disorder: Feasibility and Initial Outcomes. Ann. Emerg. Med.","DOI":"10.1016\/j.annemergmed.2021.05.013"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.15585\/mmwr.mm6533a2","article-title":"Fentanyl law enforcement submissions and increases in synthetic opioid\u2013involved overdose deaths\u201427 states, 2013\u20132014","volume":"65","author":"Gladden","year":"2016","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.15585\/mmwr.mm6634a2","article-title":"Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region\u2014United States, 2006\u20132015","volume":"66","author":"Gladden","year":"2017","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","article-title":"Deaths involving fentanyl, fentanyl analogs, and U-47700\u201410 states, July\u2013December 2016","volume":"66","author":"Halpin","year":"2017","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_44","unstructured":"Center for Disease Control and Prevention (2021, July 19). Opioid Overdose.Understanding the Epidemic, Available online: https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2105\/AJPH.2019.305412","article-title":"Polysubstance Use: A Broader Understanding of Substance Use during the Opioid Crisis","volume":"110","author":"Cicero","year":"2020","journal-title":"Am. J. Public Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of Medications for Alcohol Use Disorder in the US: Results from the 2019 National Survey on Drug Use and Health","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"460","DOI":"10.15288\/jsad.2010.71.460","article-title":"Early adoption of injectable naltrexone for alcohol-use disorders: Findings in the private-treatment sector","volume":"71","author":"Abraham","year":"2010","journal-title":"J. Stud. Alcohol Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jsat.2017.05.004","article-title":"Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders","volume":"85","author":"Venegas","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2017.03.005","article-title":"Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs","volume":"77","author":"Finlay","year":"2017","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jsat.2017.02.016","article-title":"Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment","volume":"85","author":"Robertson","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11606-017-4202-z","article-title":"Barriers to and facilitators of alcohol use disorder pharmacotherapy in primary care: A qualitative study in five VA clinics","volume":"33","author":"Williams","year":"2018","journal-title":"J. Gen. Intern. Med."},{"key":"ref_52","unstructured":"DiClemente, R.J., Salazar, L.F., and Crosby, R.A. (2013). Health Behavior Theory for Public Health: Principles, Foundations, and Applications, Jones & Bartlett Publishers."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.addbeh.2011.01.032","article-title":"Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation","volume":"36","author":"Roman","year":"2011","journal-title":"Addict. Behav."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Stoner, S.A., Arenella, P.B., and Hendershot, C.S. (2015). Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124613"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cpr.2017.10.012","article-title":"Sex and gender differences in substance use disorders","volume":"66","author":"McHugh","year":"2018","journal-title":"Clin. Psychol. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2014.03.010","article-title":"Gender and race\/ethnicity differences for initiation of alcohol-related service use among persons with alcohol dependence","volume":"140","author":"Alvanzo","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/acer.12228","article-title":"Characterizing gender differences in treatment seekers","volume":"38","author":"Lewis","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/acer.13137","article-title":"Treatment Utilization Among Adolescent Substance Users: Findings from the 2002 to 2013 National Survey on Drug Use and Health","volume":"40","author":"Haughwout","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/acer.13985","article-title":"Alcohol and Women: A Brief Overview","volume":"43","author":"McCaul","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1037\/a0035488","article-title":"Alcohol use disorder in women: Risks and consequences of an adolescent onset and persistent course","volume":"28","author":"Foster","year":"2014","journal-title":"Psychol. Addict. Behav."},{"key":"ref_61","unstructured":"Kaiser Family Foundation (2021, February 10). Status of State Medicaid Expansion Decisions: Interactive Map. Available online: https:\/\/www.kff.org\/medicaid\/issue-brief\/status-of-state-medicaid-expansion-decisions-interactive-map\/."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1176\/appi.ps.202000049","article-title":"Medicaid Expansion and Availability of Opioid Medications in the Specialty Substance Use Disorder Treatment System","volume":"72","author":"Abraham","year":"2021","journal-title":"Psychiatr. Serv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jsat.2015.10.003","article-title":"Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use","volume":"62","author":"Croff","year":"2016","journal-title":"J. Subst. Abus. Treat."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/16\/8884\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:50:04Z","timestamp":1760165404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/16\/8884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":63,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijerph18168884"],"URL":"https:\/\/doi.org\/10.3390\/ijerph18168884","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]}}}